Alecta Tjanstepension Omsesidigt Grows Stock Position in Zoetis Inc. $ZTS

Alecta Tjanstepension Omsesidigt boosted its holdings in Zoetis Inc. (NYSE:ZTS) by 24.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 882,200 shares of the company’s stock after buying an additional 172,300 shares during the period. Alecta Tjanstepension Omsesidigt owned 0.20% of Zoetis worth $129,022,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Halbert Hargrove Global Advisors LLC raised its position in Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. KERR FINANCIAL PLANNING Corp purchased a new stake in shares of Zoetis in the third quarter worth about $31,000. Financial Consulate Inc. acquired a new stake in shares of Zoetis in the third quarter valued at about $39,000. SJS Investment Consulting Inc. grew its stake in shares of Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC purchased a new stake in shares of Zoetis during the 3rd quarter valued at about $42,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Bank of America boosted their price target on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Friday, February 13th. UBS Group set a $136.00 price objective on shares of Zoetis in a research note on Thursday, January 29th. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Morgan Stanley set a $160.00 target price on shares of Zoetis in a research note on Thursday, December 18th. Finally, BTIG Research reaffirmed a “buy” rating and set a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $152.91.

Zoetis Stock Performance

Zoetis stock opened at $117.42 on Thursday. Zoetis Inc. has a 52 week low of $114.47 and a 52 week high of $172.23. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a market cap of $49.57 billion, a P/E ratio of 19.50, a price-to-earnings-growth ratio of 1.86 and a beta of 0.95. The stock has a 50 day moving average of $124.80 and a 200-day moving average of $130.99.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same period in the previous year, the business posted $1.40 EPS. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.